Pegzilarginase: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Pegzilarginase. Educational only — not medical advice.
Labeled uses
LOARGYS is indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction. This indication is approved under accelerated approval based on reduction of plasma arginine [see Clinical Studies (14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Source: FDA labeling via NIH DailyMed (set d5ceabf2…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.